How Amzeeq™ is different from other Minocycline containing products?
Amzeeq™ is the first topical minocycline to be approved by the FDA for any condition.1
Minocycline is a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, but its use is limited in some patients due to systemic side effects when taken orally. Before Amzeeq™, Minocycline has not been available as a topical treatment due to its instability in traditional topical formulations. In Amzeeq™, Foamix has leveraged its proprietary Molecule Stabilizing Technology (MST™) platform to effectively deliver minocycline in a foam-based vehicle.1
PRODUCT INFORMATION
Approval date: 18 Oct. 2019
Active ingredient: Minocycline hydrochloride
Brand name: Amzeeq™
Innovator: Foamix
Route and dosage form: Topical foam
Indication: to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older
Excipients: soybean oil, coconut oil, light mineral oil, cyclomethicone, cetostearyl alcohol, stearic acid, myristyl alcohol, hydrogenated castor oil, white wax (beeswax), stearyl alcohol, docosanol
Launch information: Launch expected in Jan. 2020 in the US.1
Foamix has entered into manufacturing and supply agreement for Amzeeq™ with ASM Aerosol-service.2
If you need information on patents/patent applications covering Foamix’s Amzeeq™, then write us at pharmacaption@gmail.com
1 Press release from Foamix dated 18 Oct. 2019.
2 Press release from Foamix dated 23 Oct. 2019.
No comments:
Post a Comment